Magoral

Quick links to important sections

Magoral

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Magoral

Quick Facts

Property Description
Active Ingredient Magnesium Oxide (MgO)
Form Oral Solid Preparations (Tablets/Capsules)
Pharmacological Class Antacid, Osmotic Laxative, Essential Mineral Supplement
Common Use Relief of acid indigestion and occasional constipation
Origin Inorganic Compound, Essential Mineral

What Type of Medicine is Magoral and What is its Composition?

Magoral is a monocomponent medicinal preparation based on the essential mineral Magnesium Oxide (MgO), recognized as an Over-the-Counter (OTC) agent. This active ingredient is an inorganic compound and an essential mineral supplied in oral solid preparations, such as tablets or capsules, for ease of ingestion. Magoral distinguishes itself by focusing solely on Magnesium Oxide, unlike certain other antacid preparations that utilize combination formulas.

The formulation is classified under the pharmacological category of Gastrointestinal Agents, reflecting the multipurpose nature of its active component, which falls into classes for Antacids, Osmotically acting laxatives, and Magnesium supplements within the Anatomical Therapeutic Chemical (ATC) classification system.


Magnesium Oxide: Dual Action and Core Benefit

Magoral's core therapeutic purpose stems from the dual action of its active substance, providing relief from two distinct, common digestive issues: acid indigestion and temporary constipation. This dual mechanism is a recognized clinical property. In the stomach, Magnesium Oxide acts as an Antacid by chemically neutralizing excess gastric acid. Concurrently, the unabsorbed portion functions as an Osmotic Laxative lower in the intestinal tract by drawing water into the bowel, which aids in promoting motility.

Beyond addressing acute digestive symptoms, the preparation serves the general benefit of delivering Elemental Magnesium (Mg^2+). This critical cation is required for normal function, and it is involved in fundamental physiological processes like nerve signal transmission and muscle contraction.

Regulatory References

  1. WHO Collaborating Centre for Drug Statistics Methodology
  2. National Library of Medicine - MedlinePlus on Magnesium

What side effects are possible with Magoral?

Possible Side Effects and Safety Information

The safety profile for Magoral (Magnesium Oxide) is officially structured around common, localized adverse effects and the rare, but serious, risk of systemic toxicity in specific populations. This information is derived exclusively from regulatory documents and authoritative government health sources.


Gastrointestinal Adverse Reactions

The most frequently documented adverse effects are related to the drug's osmotic action in the digestive tract and are generally classified as Common in regulatory labels. These effects are confined to the Gastrointestinal System and may include diarrhea (the principal expected effect), stomach pain, nausea, and abdominal cramping.


Risk of Systemic Toxicity

While uncommon in individuals with normal health, the official labels document Hypermagnesemia (Magnesium Toxicity) as a serious adverse reaction, particularly in the context of high intake or impaired elimination. Since magnesium is cleared by the kidneys, severe toxicity is principally a risk factor for individuals with compromised renal function. Signs of severe toxicity, as described in regulatory text, include hypotension, depressed muscle reflexes, and potential respiratory depression.


Safety-Related Restrictions

Regulatory documents include explicit restrictions regarding use. Magoral is formally contraindicated in patients with severely reduced renal impairment (kidney function) due to the high risk of systemic accumulation. It is also contraindicated in individuals with known hypersensitivity to the active ingredient or with pre-existing gastrointestinal obstructions or ileus. Furthermore, the labeling notes that the preparation may interact with certain prescription drugs, potentially decreasing their absorption.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Magoral (Magnesium Oxide) results in a state of Hypermagnesemia, where excessive magnesium concentrations lead to a spectrum of officially documented systemic effects.

Documented Manifestations

The clinical presentation of overdose typically progresses from early gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, to neuromuscular and cardiovascular signs. Officially recognized manifestations include muscle weakness, lethargy, drowsiness, confusion, and the loss of deep tendon reflexes.

Severe Outcomes and Emergency Action

Severe hypermagnesemia is classified by regulators as potentially life-threatening due to the risk of progression to hypotension (low blood pressure), bradycardia (slowed heart rate), respiratory depression, and, in critical cases, cardiac arrest and coma. Immediate medical attention must be sought for any symptom suggesting severe toxicity. Contacting emergency services immediately is required upon observing signs like severe confusion or difficulty breathing.

Official Management Notes

Management protocols documented in regulatory sources specify the need for product discontinuation and specialized intervention. This may include administering Intravenous Calcium Gluconate as a specific agent to counteract acute effects, enhancing magnesium excretion using IV fluids and diuretics, or requiring dialysis (hemodialysis) for patients with renal failure.

Population-Specific Risk

Regulatory documents explicitly identify patients with renal impairment (kidney disease) as being at significantly increased risk of severe hypermagnesemia due to the impaired ability to excrete excess magnesium.

Therapeutic Uses of Magoral

What Magoral Treats: Main Uses and Benefits

Magoral is applied across domains where additional symptomatic support is needed, generally focusing on common gastrointestinal disturbances and essential mineral intake.

Therapeutic Focus

This medicine is commonly used to address situations involving acid indigestion, heartburn, and sour stomach, as well as managing occasional constipation and managing symptoms associated with mild deficiency of Elemental Magnesium. Magoral is relevant when supportive symptom management is appropriate for episodes where discomfort arises from these conditions.

This medication is used in the management of symptoms related to physical discomfort and systemic imbalance. It assists with maintaining functional stability and supports general well-being during symptomatic phases. It helps address groups of symptoms that may appear suddenly or fluctuate, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Digestive Discomfort
Primary Target Symptoms Heartburn, sour stomach, infrequent bowel movements
Use Context Short-term symptomatic assistance for acute episodes
Benefit Focus Easing overall symptom burden and supporting functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Magoral?

Eligibility for use of magnesium-containing products like Magoral (magnesium hydroxide) is determined by regulatory bodies based on age, specific pre-existing health conditions, and current physiological status.

Populations for Whom Use is Contraindicated

Official documents define use as contraindicated in patients with:

  • Severe Renal Impairment/Failure: Because magnesium is eliminated by the kidneys, severe kidney dysfunction significantly increases the risk of hypermagnesemia (excess magnesium in the blood), which can lead to serious toxicity.
  • Hypermagnesemia: An existing abnormally high level of magnesium in the blood.
  • Hypersensitivity: Known allergy or severe reaction to magnesium salts or any ingredient in the product.
  • Intestinal Obstruction: Certain serious gastrointestinal conditions like intestinal obstruction disorders or fecal impaction.

Age-Related and Restricted Use

  • Pediatric Exclusion: Over-the-counter (OTC) use is generally not recommended in children under 2 years of age, and often not established or restricted for use in children under 6 or 12 years, depending on the specific product and intended purpose (antacid vs. laxative).
  • Consultation Required: Patients who have stomach pain, nausea, or vomiting or a sudden change in bowel habits lasting longer than two weeks must consult a healthcare professional prior to use. This also applies to individuals on a magnesium-restricted diet.

Pregnancy and Lactation

Use during pregnancy or while breastfeeding requires seeking advice from a healthcare provider to assess the individual risk-benefit profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Magoral, which contains Magnesium Oxide, participates in documented interaction patterns that are officially detailed in regulatory labeling, primarily affecting the absorption and systemic exposure of other substances.


Drug-Drug Interactions: Reduced Absorption

The co-administration of Magoral with many oral medications results in a decreased absorption of the second drug. This is a pharmacokinetic interaction generally caused by the magnesium cation's ability to chelate (bind) other molecules in the stomach, or by the antacid action that increases gastric pH. These effects reduce the other drug's plasma concentration.

  • Antibiotics: Absorption is significantly reduced for both tetracyclines (e.g., doxycycline) and fluoroquinolones (e.g., ciprofloxacin).
  • Other Oral Agents: Absorption is also impaired for bisphosphonates (e.g., alendronate), thyroid hormones (e.g., levothyroxine), and certain antivirals.

Mandatory Administration Timing Rules

Official labeling requires specific separation times to minimize the risk of absorption interactions:

  • Antibiotics: Tetracyclines and fluoroquinolones must be administered at least two hours before or four to six hours after taking magnesium oxide.
  • Bisphosphonates: Administration must be separated by at least two hours.
  • General Rule: A separation of at least two hours is required for most other oral medications.

Pharmacodynamic and Clearance Interactions

  • Systemic Exposure: Co-administration with certain diuretics (e.g., potassium-sparing types) can reduce the renal clearance of magnesium, leading to increased systemic magnesium exposure.
  • Potentiation: Magnesium can potentiate the effects of neuromuscular blocking agents, increasing the risk of central nervous depression, a documented pharmacodynamic interaction.

Population-Specific Restrictions

The most critical population-specific interaction is the increased risk of hypermagnesemia in patients with renal dysfunction (impaired kidney function), as magnesium is primarily eliminated by the kidneys. Use is contraindicated in cases of severe renal impairment.

Mechanism of Action

Magoral, a magnesium-containing agent, functions as a cofactor essential to over 300 enzymatic reactions, including those involving ATP metabolism and oxidative phosphorylation. Systemically, the magnesium cation acts as a physiological calcium channel blocker, modulating the transmembrane flux of calcium ions. This interaction regulates cellular excitability, influencing both cardiac and neuromuscular tissues. In the cardiovascular system, this antagonism slows atrioventricular nodal conduction and decreases myocardial excitability. Within the nervous system, the cation blocks peripheral neuromuscular transmission by inhibiting the presynaptic release of the neurotransmitter acetylcholine at the neuromuscular junction. In the gastrointestinal tract, the unabsorbed magnesium ions exert an osmotic effect, retaining water in the intestinal lumen. This fluid retention increases the intraluminal volume, stimulating colonic peristalsis and enhancing bowel motility. Furthermore, the magnesium hydroxide component neutralizes gastric hydrochloric acid through a direct chemical reaction, increasing gastric pH and inactivating the protease pepsin.

Dosage and Administration Information

Magoral (Magnesium Oxide) is administered orally as a solid tablet preparation, commonly available in a 400 mg strength. The administration protocols are based on its use as an antacid or an essential mineral supplement.

Official Dosing and Frequency

The standard adult dosing schedule for acid indigestion is 400 mg (one tablet) taken twice a day. For use as a supplement, the typical range is 400 mg to 800 mg daily. The maximum recommended dose is 800 mg (two tablets) in any 24-hour period.

Administration Constraints and Duration

Proper administration involves swallowing the tablet whole with water. To prevent reduced absorption of co-administered drugs, Magoral is taken at least two hours apart from other oral medications. When used for supplementation, the medicine may be taken with food. The maximum dosage is designated for short-term use and is generally not continued for more than two weeks.

Caution is typically indicated in specific patient populations: administration to older adults usually begins at the lower end of the dosing range, and monitoring is necessary for individuals with compromised kidney function. If a dose is missed, the practice is to take it as soon as remembered, which includes avoiding doubling the next dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Magoral

This overview summarizes the official research and study landscape for Magoral (Magnesium Oxide). It focuses strictly on what clinical research has explored and what the regulatory evidence suggests, without offering any clinical advice, instructions on use, or details on safety.


Evidence for Use in Occasional Constipation

Research examined Magoral in the context of conditions associated with acute or disruptive episodes of occasional constipation. Studies included short-term, randomized controlled trials (RCTs), where Magoral was evaluated in adults with functional constipation. The research explored how symptoms change over time by monitoring patient-reported outcomes describing perceived discomfort and measuring functional changes, such as the frequency of spontaneous bowel movements and stool consistency.

In these trials, studies observed patterns related to an increase in the reported number of weekly bowel movements in participants receiving the medicine. Follow-up durations were limited in many controlled trials, focusing only on the short-term outcomes. Long-term outcomes are not fully established globally, and evidence is limited, with results applying only to the populations studied.


Evidence for Use in Acid Indigestion and Heartburn Relief

Magoral was studied for its use in the context of acute symptoms of acid indigestion and heartburn. This research included pharmacological studies that measured the medicine's chemical capacity to neutralize acid. These studies are relevant in trials assessing short-term or episodic symptom patterns by monitoring the acute change in stomach pH levels after administration.

Pharmacological assessments reported that the compound exhibits a rapid chemical neutralizing effect on gastric acid. The findings describe the observed pattern of the medicine altering the gastric environment. Comparative evidence is lacking for Magoral as a monotherapy for complex or long-term acid-related issues. Furthermore, many controlled symptom studies were observed in some studies to use combination antacid formulas that contained a magnesium component.


Evidence for Magnesium Supplementation Status

Research explored Magoral's bioavailability by tracking changes in serum and urinary magnesium concentrations. Other studies monitored outcomes related to systemic or functional imbalance in populations where researchers examined factors like blood pressure or nocturnal muscle cramps. Pharmacokinetic studies reported that the bioavailability of Magnesium Oxide was observed in some studies to be lower compared to some organic magnesium salts. Clinical studies reported varying measurements of change in serum magnesium concentrations following supplementation.

Key Studies & References

  1. Antacids - StatPearls - NCBI Bookshelf - NIH (Authority on Antacid Mechanism and Use)
  2. Label: ANTACID - Magnesium Oxide Tablet - DailyMed (FDA OTC Monograph Data)
  3. Magnesium Fact Sheet for Consumers - NIH Office of Dietary Supplements (Authority on Magnesium Status and Deficiency)

Frequently Asked Questions (FAQ)

Common questions about Magoral (FAQ)


Q: How quickly does Magoral start working?

Magoral is designed to work in two ways. As an antacid, the chemical neutralizing effect on stomach acid is generally described in studies as rapid. However, the onset of the laxative effect, which relies on the medicine reaching the lower intestinal tract, may take longer.


Q: What is the biggest difference between Magoral and other drugs for the same condition?

According to official product information, Magoral is described as a monocomponent medicine, meaning its effects are attributed solely to its active ingredient, Magnesium Oxide. This distinguishes it from certain other products used for similar conditions that may utilize combination formulas.


Q: Do I need to avoid any specific foods or drinks while taking Magoral?

Official guidelines recommend separation of administration by at least two hours from other oral medications to prevent reduced absorption. When the medicine is used for supplementation, it may be taken with food, but no specific foods or drinks are formally restricted.


Q: Can Magoral be taken with common pain relievers like ibuprofen or acetaminophen?

Because the active component can bind other oral medications, resulting in decreased absorption of the other drug, official guidelines recommend separating the administration of Magoral from most oral drugs. The general rule is to maintain a separation of at least two hours.


Q: Are there any long-term effects associated with taking Magoral?

Regulatory labeling indicates that the maximum dosage is designated for short-term use and that the medicine is not to be continued for more than two weeks without consultation from a healthcare professional.


Q: Is Magoral safe for older adults or the elderly population?

Official usage principles state that administration to older adults should generally begin at the lower end of the dosing range. Official guidance indicates that caution and monitoring is indicated for some individuals in this population, particularly those with compromised kidney function.


Q: What does the research say about Magoral's effectiveness in real-world use?

Evidence is often based on short-term, randomized controlled trials. Studies have reported observing patterns related to an increase in bowel movements and a rapid change in stomach pH. Long-term outcomes or real-world effectiveness are described as not fully established globally, with results limited to the populations studied in the trials.


Q: Does Magoral affect blood pressure or heart rate?

Official documents state that the medicine's mechanism can influence cardiac tissues by slowing atrioventricular nodal conduction. Additionally, hypotension (low blood pressure) is listed as a potential sign of severe systemic toxicity (hypermagnesemia), which is rare but possible with high intake or impaired kidney function.


Q: Is Magoral considered habit-forming or addictive?

Magoral is an Over-the-Counter (OTC) medicine. According to regulatory agencies, it is not designated as a controlled or scheduled substance with potential for abuse.


Q: Why do doctors prescribe Magoral for a different condition than its main use?

Official regulatory labels only define the medicine’s supported uses as acid indigestion and temporary constipation. Discussion of uses outside of this established regulatory label is not present in official product information.


Q: Is there any evidence about Magoral use in children?

Over-the-Counter (OTC) use is generally not recommended in children under 2 years of age. Use is often established or restricted for older children depending on the product’s specific intended purpose. Regulatory guidance recommends that professional advice be sought regarding use in children.


Q: Do clinical trials for Magoral show strong results?

The evidence overview reports that studies showed patterns related to an increase in weekly bowel movements when used for constipation. For acid indigestion, pharmacological studies reported a rapid chemical neutralizing effect on gastric acid.


Q: Does Magoral interact with alcohol, according to the official label?

Official Over-the-Counter (OTC) labels for Magnesium Oxide do not typically contain specific warnings or restrictions regarding the moderate use of alcohol.


Q: Why do some people stop taking Magoral?

The medicine’s most frequently documented adverse effect is diarrhea due to its osmotic action in the digestive tract. This, along with potential abdominal cramping, is the primary expected and common reason why patients might discontinue use.


Q: What if the expected effect of Magoral doesn't happen?

Official guidance indicates that a healthcare professional should be consulted if symptoms worsen or do not improve after the maximum use period of two weeks. Consultation is also recommended if a sudden change in bowel habits lasts longer than two weeks.


Q: Are there any specific laboratory tests needed before starting Magoral?

The primary risk for toxicity relates to impaired kidney function, as the kidneys clear magnesium from the body. Official information states that caution and possible monitoring is indicated for individuals with compromised kidney function due to this risk of systemic accumulation and toxicity.


Q: Does Magoral have known interactions with common cold or flu medicines?

The regulatory rule for drug interactions states that the general mechanism of reduced absorption applies to many oral medications. Common cold and flu medicines taken orally may also need to be separated from Magoral by at least two hours.


Q: What is the pregnancy risk category for Magoral?

The US FDA has amended its rules, and a specific risk classification is Not Assigned. Regulatory guidance states that use during pregnancy or breastfeeding is subject to professional advice to assess the individual risk.


Q: Does the onset of action differ for the various available forms of Magoral?

Official information indicates that the onset of symptomatic relief will differ based on the intended purpose. The rapid antacid effect begins in the stomach, while the slower laxative effect requires passage to the lower intestinal tract.


Q: Is Magoral safe to take with a multivitamin?

The regulatory principle of drug interaction for Magoral involves chelation (binding). Because of this, taking it with a multivitamin may reduce the absorption of other minerals and vitamins contained within the supplement.


Q: Are there any contraindications related to having an existing heart condition?

While the medicine’s mechanism can influence cardiac tissue, the formal contraindications listed in official documents are primarily related to conditions that increase the risk of toxicity, specifically severe renal impairment and hypermagnesemia.


Q: What is the expected experience when starting treatment with Magoral?

Patients can generally expect symptomatic relief from acid indigestion or constipation, which is the core benefit. This experience may be accompanied by the possibility of the common adverse effects, such as diarrhea, stomach pain, or abdominal cramping.


Q: Are there different strengths or forms of Magoral available?

Official labeling confirms the medicine is commonly available in a 400 mg strength. It is supplied in various oral solid preparations, which may include both tablets and capsules.


Q: What is the purpose of Magoral if it only controls symptoms and doesn't cure?

The core purpose is to provide symptomatic relief through its dual action. The active ingredient chemically neutralizes excess gastric acid and acts as an osmotic laxative by drawing water into the bowel to support motility.

How should Magoral be stored and disposed of?

How to Store and Dispose of Magoral?

Storage and disposal instructions for Magoral (Magnesium Oxide) are based on regulatory guidance designed to maintain product quality and ensure public safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (e.g., 20°C to 25°C).
Container Integrity The container must be kept tightly closed to protect the contents from moisture, due to the hygroscopic nature of the active ingredient.
Prohibited Areas Do not store in the bathroom or areas subject to excess heat or excess moisture.

Handling and Child Safety

Official labeling mandates that the product must be kept out of the sight and reach of children to prevent accidental ingestion. All medication containers should be securely stored in an up and away location.

Disposal Instructions

For disposal of unused or expired Magoral, the preferred method is an authorized drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed bag, and discarded with household trash. The medication must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Magoral found in:

A-Z Index: